Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

Completed · Phase 4

Conditions studied: Breast Cancer, Multiple Myeloma, Prostate Cancer

In brief

Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.

Key facts

Study ID

NCT00029224

Run by

Novartis

People needed

500

Starts

2001-10-01

Expected to finish

2002-11-01

Last updated by the study team

2012-02-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent
• Greater than 18 years of age
• Proof of breast cancer, multiple myeloma or prostate cancer
• Diagnosis of at least one cancer-related bone lesion
• If patient is of child-bearing potential, negative pregnancy test and on a medically recognized form of contraception
• ECOG performance status of 0,1 or 2
• Ability to read, understand and write English or Spanish language
• Normal renal function
• Corrected serum calcium equal to or greater than 8mg/dl Exclusion Criteria
• clinically symptomatic brain metastases
• hypersensitivity to Zometa or other bisphosphonates
• pregnant or lactating

Where it is running

• Stockton Hematology Oncology Medical Group — Stockton, California, United States
• Osceola Cancer Center — Kissimmee, Florida, United States
• Nevada Cancer Center — Las Vegas, Nevada, United States
• Hematology-Oncology Associates PC — Albuquerque, New Mexico, United States
• New Mexico Oncology Hematology Consultants — Albuquerque, New Mexico, United States
• Hematology Oncology Associates, PC — Medforo, Oregon, United States
• Virginia Physicians, Inc — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.